Recombinant CD79B (Polatuzumab Biosimilar) antibody

Catalog No. ABIN7795113

The Humanized Monoclonal anti-CD79B (Polatuzumab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect CD79B (Polatuzumab Biosimilar) in samples from Human.

Quick Overview for Recombinant CD79B (Polatuzumab Biosimilar) antibody (ABIN7795113)

Target: CD79B (Polatuzumab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CD79B (Polatuzumab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD79B (Polatuzumab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Polatuzumab Biosimilar, Human CD79B Monoclonal Antibody

Characteristics: What is polatuzumab biosimilar research grade? Polatuzumab is a humanized IgG1-kappa monoclonal antibody against the human CD79B protein, which is ubiquitously expressed on the surface of malignant B cells. Polatuzumab vedotin is used to treat diffuse large B-cell lymphoma (DLBCL) after at least two other cancer treatments did not work or have stopped working. It is given in combination with bendamustine (Bendeka, Treanda) and a medicine that contains rituximab (Rituxan). Polatuzumab vedotin works by attaching to CD79b and releasing a toxic substance that kills the cancer cells. Polatuzumab biosimilar uses the same protein sequences as the therapeutic antibody polatuzumab.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD79B

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD79B (Polatuzumab Biosimilar)

Target: CD79B (Polatuzumab Biosimilar)

Alternative Name: Polatuzumab Biosimilar

Target Type: Biosimilar